Skyrizi vs Tremfya
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| US Skyrizi | US Tremfya | |
|---|---|---|
| Generic name | risankizumab | guselkumab |
| Drug class | IL-23 Inhibitor (Biologic) | IL-23 Inhibitor (Biologic) |
| Treats | Plaque psoriasis, psoriatic arthritis, Crohn's disease | Plaque psoriasis, psoriatic arthritis |
| Category | Autoimmune | Autoimmune |
| Manufacturer | AbbVie | Janssen |
| Year approved | 2019 | 2017 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $480M | $140M |
| Common side effects | Respiratory infections, Headache, Fatigue, Injection site reactions | Respiratory infections, Headache, Injection site reactions, Joint pain |
Frequently asked questions
Is Skyrizi or Tremfya better?
Neither is universally "better." Skyrizi (risankizumab) and Tremfya (guselkumab) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Skyrizi and Tremfya?
Skyrizi is a IL-23 Inhibitor (Biologic) made by AbbVie, while Tremfya is a IL-23 Inhibitor (Biologic) made by Janssen. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Skyrizi has the larger estimated TV advertising budget of the two.